CHICAGO GYN ONCOLOGY UPDATES

CME INFORMATION

PHYSICIAN CREDIT

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of **4.25** *AMA PRA Category 1 Credits* $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT

University of Chicago Medicine is approved as a provider of nursing continuing professional development by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. (OBN-001-91)

This live activity is designated for a maximum of **4.25** continuing nursing education units

AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDIT Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

OTHER HEALTHCARE PROFESSIONAL CREDIT

Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.




The University of Chicago Center for Continuing Medical Education 5841 S. Maryland Ave., MC 1137 Chicago, IL 60637

Follow us on Twitter: @UChicagoCME

FOR MORE INFORMATION AND TO REGISTER VISIT:

cme.uchicago.edu/GynOncUpdates2022 **QUESTIONS?** Contact Polly Rossi at

Polly@meetingachievements.com Or 219.465.1115



PROGRAM INFORMATION

The all-virtual Chicago GYN Oncology Updates will celebrate the 2021-2022 theme of the SGO presidency of Dr. Diane Yamada, "Building Bridges and Breaking Barriers" by providing access to the most important educational and scientific updates for women's healthcare professionals from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. It will include information and resources for members of the entire gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiation therapy, and surgery. This highly interactive activity will provide participants with distillations of advances in the fields of ovarian cancer, endometrial cancer, and cervical cancer including options for treatment for women with ovarian cancer after progression on PARP inhibitors and appropriate use of new therapies such as antibody-drug conjugates and immunotherapy/antiangiogenic tyrosine kinase inhibitor combinations. Information on appropriate use and applications of genomic testing in GYN sarcomas will also be presented. The most recent updates on efforts to improve health equity will be presented. In addition, the critical importance of clinical research will be highlighted with presentations of Chicago area investigator-initiated trials (IIT) in order to foster ongoing collaborations.

TARGET AUDIENCE

This activity is designed for gynecologic oncologists, medical oncologists, radiation oncologists, pathologists, gynecologists, trainees, research scientists, nurses, nurse practitioners, physician assistants, and other healthcare professionals dedicated to the care of patients with gynecologic malignancies.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Define the mechanisms of action and side effect profiles of new gynecologic cancer therapies;
- 2. Select treatment options for women with ovarian cancer who have progressed on PARP inhibitor therapy;
- **3.** Discuss appropriate application of the category of "platinum-resistant" in the therapy of women with ovarian cancer:
- Identify appropriate settings for use of antiangiogenic therapies in ovarian carcinomas;
- Distinguish when to prescribe antiangiogenic/ immunotherapy combination treatment appropriately for women with endometrial cancer;
- **6.** Describe how to prevent and manage toxicities of antiangiogenic/immunotherapy treatment in women with endometrial cancer:
- State how to order appropriate diagnostic testing for women with gynecologic sarcomas;
- **8.** Recommend appropriate adjuvant therapy for women with gynecologic sarcomas;
- Recognize how to address contextual barriers to health equity related to gynecologic cancer;
- **10.** Discuss the potential application of ongoing gynecologic cancer research studies in the Chicago area.

SCAN TO REGISTER!





FRIDAY MAY 13, 2022

8:00 am WELCOME

Gini Fleming, MD & Diane Yamada, MD

FIRST HALF MODERATOR:

Elena Moore, MD

OVARIAN CANCER SESSIONS

8:05 am KEYNOTE: Landscape in Therapy of

Recurrent Ovarian Cancer

Michael Bookman, MD

8:35 am SGO Ovarian Cancer Abstracts

Emma Barber, MD, MS

8:55 am Q & A Session

WHIRLWIND TOUR OF IITS IN THE CITY PART 1 SESSIONS

9:05 am GR and Response to Therapy in Ovarian Cancer

Katherine Kurnit, MD, MPH

9:10 am Repurposing Minoxidil for the Treatment of

Recurrent Platinum Resistant Ovarian Cancer

Margaret Liotta, DO, MS

9:15 am A Phase I Trial of Talimogene Laherparepvec

(TVEC) for the Treatment of Peritoneal Surface

Malignancies (TEMPO)

Shannon MacLaughlan David, MD, MS

9:20 am BREAK

9:50 am SPECIAL TALK: Adoptive Immunotherapy for

GYN Malignancies Michael Bishop, MD

SECOND HALF MODERATOR: Najeeb Mohideen, MD, FASTRO

UTERINE/CERVICAL CANCER SESSIONS

10:20 am KEYNOTE: Update on Uterine Sarcomas

Martee Hensley, MD, MSc, FASCO

11:00 am SGO Abstract Review: Endometrial Cancer

& Uterine Sarcomas Andras Ladanyi, MD, PhD

WHIRLWIND TOUR OF IITS IN THE CITY PART 2 SESSIONS

11:20 am Phase II Study of Concurrent and Sequential

Carboplatin and Paclitaxel with Adjuvant Radiotherapy for High Risk Endometrial Cancer

Matthew Harkenrider, MD

11:25 am Ashwagandha for Cervical Cancer Prevention and

Treatment: A Pilot Clinical and Translational Trial

Shannon MacLaughlan David, MD, MS

11:30 am SGO Abstract Review: Cervical Cancer/RT Updates

Jocelyn Ray, MD, PhD

11:50 am **BREAK**

BRIEF UPDATE ON NOVEL TOXICITIES SESSION

12:05 pm Ocular Toxicities with Antibody-Drug Conjugates

Christine Deskovich, MSN

12:10 pm SGO Diversity/Population Science Abstracts

Ana Tergas, MD, MPH

12:30 pm BREAKOUT ROOMS: Meet and Chat with the Faculty

Ovarian Cancer Breakout

Michael Bookman, MD and Emma Barber, MD, MS

Adoptive Immunotherapy Breakout

Michael Bishop, MD and Kunle Odunsi, MD, PhD

Cervix and Sarcomas Breakout
Martee Hensley, MD, MSc, FASCO and

Jocelyn Ray, MD, PhD

1:00 pm ADJOURN